Researchers at the University of California, Los Angeles (UCLA) have achieved a significant breakthrough in gene therapy for cystic fibrosis, successfully inserting a full, healthy copy of the disease-causing gene into human airway cells using lipid nanoparticles. The approach, detailed in a study published in Advanced Functional Materials on February 17, 2026, offers a potential path toward a universal treatment for all genetic variations of the disease.
Cystic fibrosis, a progressive and debilitating genetic disorder, affects the lungs, pancreas, and other organs. It’s caused by mutations in the CFTR gene, which regulates the flow of salt and water in and out of cells. Currently, treatments known as CFTR modulators exist, but they are ineffective for approximately 10% of patients who produce little to no functional CFTR protein, leaving them with limited therapeutic options. “For those patients, gene therapy isn’t just an improvement – it’s really the only option,” said Brigitte Gomperts, co-author of the study and associate director of translational research at the UCLA Broad Stem Cell Research Center.
The UCLA team’s innovation lies in its use of lipid nanoparticles – the same technology used in mRNA vaccines – to deliver the complete CFTR gene, along with the necessary gene-editing tools, directly into airway cells. Unlike traditional gene therapies that rely on viral vectors, this non-viral delivery system avoids potential issues with cost, limited cargo capacity, and immune responses. The nanoparticles were engineered to carry CRISPR machinery to precisely cut DNA, guide molecules to target the correct genomic site, and a DNA template encoding a functional CFTR gene.
“Getting all of that into a single particle – especially a gene as large as CFTR – is something that hadn’t been shown before,” explained Ruth Foley, the study’s first author and a recent PhD graduate from the Jonas lab at UCLA. The researchers successfully delivered the healthy gene into 3-4% of the cells in a lab setting, but even this tiny correction rate resulted in a restoration of 88-100% of normal CFTR channel function. This high level of recovery is attributed to the gene’s optimized design, developed in collaboration with Donald Kohn’s lab at UCLA, which maximizes protein production once inside the cell.
The approach differs from existing therapies that deliver messenger RNA, which requires repeated doses. By directly inserting the corrected gene into the genome, the UCLA team hopes to achieve a durable, one-time treatment. However, researchers acknowledge that reaching airway stem cells, which reside deep within the lung’s protective lining and continuously regenerate airway cells, remains a significant challenge. “These stem cells are long-lived and constantly regenerate the airway,” Gomperts said. “If you can correct them, you could, in theory, have a lasting source of healthy cells.”
Steven Jonas, senior author of the study and a member of the UCLA Broad Stem Cell Research Center, emphasized that this research represents a proof of concept. “It shows that we can package and deliver the right genetic cargo. The next challenge is getting it to the right cells in the body.” The team is now focused on improving delivery methods to target airway stem cells and overcome the lung’s natural defenses, as well as the increased mucus present in cystic fibrosis patients.
The modular nature of the lipid nanoparticle platform offers potential for broader applications beyond cystic fibrosis. Researchers believe it could be adapted to treat other genetic lung diseases and potentially conditions affecting other tissues, particularly those caused by large genes with numerous possible mutations. “This kind of platform gives you room to iterate,” Foley said. “If you necessitate to re-dose or adapt the cargo for a different disease, you’re not starting from scratch.”
